Agenus Inc. (AGEN)
NASDAQ: AGEN · Real-Time Price · USD
4.210
+0.150 (3.69%)
Apr 8, 2026, 11:44 AM EDT - Market open
Agenus Revenue
In the year 2025, Agenus had annual revenue of $114.20M with 10.37% growth. Agenus had revenue of $34.20M in the quarter ending December 31, 2025, with 27.45% growth.
Revenue (ttm)
$114.20M
Revenue Growth
+10.37%
P/S Ratio
1.37
Revenue / Employee
$1,409,827
Employees
81
Market Cap
161.66M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 114.20M | 10.73M | 10.37% |
| Dec 31, 2024 | 103.46M | -52.85M | -33.81% |
| Dec 31, 2023 | 156.31M | 58.29M | 59.47% |
| Dec 31, 2022 | 98.02M | -197.64M | -66.85% |
| Dec 31, 2021 | 295.67M | 207.50M | 235.34% |
| Dec 31, 2020 | 88.17M | -61.88M | -41.24% |
| Dec 31, 2019 | 150.05M | 113.26M | 307.92% |
| Dec 31, 2018 | 36.78M | -6.09M | -14.21% |
| Dec 31, 2017 | 42.88M | 20.30M | 89.95% |
| Dec 31, 2016 | 22.57M | -2.24M | -9.04% |
| Dec 31, 2015 | 24.82M | 17.84M | 255.67% |
| Dec 31, 2014 | 6.98M | 3.93M | 129.13% |
| Dec 31, 2013 | 3.05M | -12.92M | -80.92% |
| Dec 31, 2012 | 15.96M | 13.20M | 479.17% |
| Dec 31, 2011 | 2.76M | -603.84K | -17.97% |
| Dec 31, 2010 | 3.36M | 25.17K | 0.75% |
| Dec 31, 2009 | 3.33M | 683.36K | 25.78% |
| Dec 31, 2008 | 2.65M | -2.90M | -52.25% |
| Dec 31, 2007 | 5.55M | 4.86M | 702.20% |
| Dec 31, 2006 | 692.14K | 62.16K | 9.87% |
| Dec 31, 2005 | 629.98K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Karyopharm Therapeutics | 146.07M |
| Black Diamond Therapeutics | 70.00M |
| Spero Therapeutics | 66.80M |
| Sangamo Therapeutics | 39.55M |
| Innate Pharma | 10.57M |
| Alpha Cognition | 10.22M |
| Equillium | 4.39M |
| Oramed Pharmaceuticals | 2.00M |
AGEN News
- 5 days ago - Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026 - Business Wire
- 7 days ago - Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer - Business Wire
- 12 days ago - Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access - Business Wire
- 21 days ago - Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer - Business Wire
- 23 days ago - Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized - Business Wire
- 4 weeks ago - Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs - Business Wire
- 4 weeks ago - Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update - Business Wire
- 6 weeks ago - Agenus Presents Biomarker Data Demonstrating Survival Stratification in MSS mCRC and Other Immunologically Cold Tumors Treated with BOT+BAL - Business Wire